While this happened, JP Morgan downgraded its Organon & Co [OGN] rating to an Underweight from a a Neutral in a research note published on September 06, 2024; the price target was increased to $20 from $18. A number of analysts have revised their coverage, including Goldman’s analysts, who decreased its forecast for the stock in early November from “a Buy” to “a Neutral”. Barclays began covering OGN with “an Overweight” recommendation on September 21, 2023. Raymond James started covering the stock on March 16, 2023. It rated OGN as “an Outperform”.
Price Performance Review of OGN
On Monday, Organon & Co [NYSE:OGN] saw its stock fall -4.41% to $10.63. Over the last five days, the stock has lost -4.92%. Organon & Co shares have fallen nearly -28.75% since the year began. Nevertheless, the stocks have fallen -40.51% over the past one year. While a 52-week high of $23.10 was reached on 02/13/25, a 52-week low of $10.75 was recorded on 04/21/25. SMA at 50 days reached $14.34, while 200 days put it at $17.11.
Levels Of Support And Resistance For OGN Stock
The 24-hour chart illustrates a support level at 10.35, which if violated will result in even more drops to 10.08. On the upside, there is a resistance level at 11.00. A further resistance level may holdings at 11.38. The Relative Strength Index (RSI) on the 14-day chart is 29.39, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.34, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 95.96%. Stochastics %K at 7.24% indicates the stock is a buying.
How much short interest is there in Organon & Co?
A steep rise in short interest was recorded in Organon & Co stocks on 2025-03-31, dropping by -2.7 million shares to a total of 15.13 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-28 was 17.84 million shares. There was a decline of -17.87%, which implies that there is a negative sentiment for the stock.
